Login to Your Account



Clinic Roundup


Tuesday, June 5, 2012
• FibroGen Inc., of San Francisco, reported preliminary findings from two ongoing Phase II trials, demonstrating that FG-4592, its oral hypoxia-inducible factor prolyl hydroxylase inhibitor, reduced blood pressure in hypertensive patients, reduced cholesterol levels and improved the ratio of high-density lipoprotein to low-density lipoprotein in lipid profiles in patients with chronic kidney disease (CK). FG-4592 is in development for anemia in CKD.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription